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Objectives
At the conclusion of this session, the participant 
will be able to accomplish the following:
 Discuss the current status of measles outbreaks in 
the U.S.
 Describe the clinical presentation of measles and 
the guidelines for patient assessment and 
management
 Outline CDC vaccination recommendations for the 
general public, international travelers, and 
healthcare professionals
 Identify CDC measles resources and training 
materials for clinicians 
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What is Measles
 Febrile rash illness caused by measles virus
 Among the most contagious of infectious diseases
 Preventable with a highly effective vaccine that is 
recommended in routine immunization schedules
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Measles Transmission
 Transmitted via respiratory droplets and aerosol
 spread by coughing and sneezing, close personal contact or direct 
contact with infected nasal or throat secretions
 Contagious from 4 days before to 4 days after rash 
onset
 R0 = 12-16 with secondary attack rates in susceptible 
household contacts ~ 90%
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Clinical Presentation
 Prodrome (2-4 days)
 Fever (up to 105oF)
 Cough, Coryza, and/or Conjunctivitis 
(the three “C’s)
 Enanthem (on mucous membranes) (Koplik spots)
 Rash ~14 days after exposure (range 7-21 days)
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Measles Rash
 Erythematous 
maculopapular rash
 Spreads from head to trunk to 
extremities
 May become confluent
 Rash lasts for 5-6 days and 
fades in order of 
appearance
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Measles Complications 
Diarrhea 8%
Otitis media 7-9%
Pneumonia 1-6%
Encephalitis 1 per 1,000 cases
Death 1 -3 per 1,000 cases
Subacute Sclerosing
Panencephalitis (SSPE)
1 per 100,000 cases 7-10 
years after measles 
More common in children < 5 years and adults
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Global Burden of Measles
 Deaths
 Estimated 2.6 million deaths/year in 1980
 78% decrease in estimated deaths from 2000 to 2012
122,000 deaths in 2012 (~14 deaths/hour) 
 Remains a leading cause of vaccine preventable deaths in children 
< 5 years old
 Complications with sequelae include blindness
 Cases
 Estimated 20 million per year
 77% decrease in reported measles incidence from 2000 to 2012
12
13
Global transmission patterns of measles viruses from 
the Philippines, 2014
B3 D9
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Measles Annual Disease Burden U.S.
Decade Prior to Vaccine (1950s)
 3-4 million estimated and ~ 500,000 reported cases
 48,000 hospitalizations
 4,000 encephalitis cases
 450-500 deaths
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Measles and MMR Vaccines
 Live, viral vaccines
 Measles vaccine licensed in 1963
 Combination MMR vaccine licensed in 1971
Only MMR vaccine is available now in the US
 Excellent safety profile with 50+ years use
 Low risk of febrile seizures in children 12-23 months (1 in 3,000 doses)
 Temporary pain/stiffness in joints, mostly in teenage or adult women
 Temporary low platelet count – ITP (~ 1 out of 30,000 doses)
 Vaccine Effectiveness
 1-dose: ~93%
 2-dose: ~97%
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Reported Measles Incidence
United States, 1992-2014*
1 case/million
Measles elimination declared
*2014 case count preliminary as of June 20
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Measles Elimination* in the U.S.
• Declared in 2000 and achieved due to:
– High two-dose vaccine coverage
– High quality measles surveillance and response
– Improved measles control in the World Health 
Organization Region of the Americas
• Elimination does not mean “gone forever”  -
imported cases and limited spread occur every 
year
* Defined as interruption of continuous measles transmission for lasting > 12 months
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Measles Cases and Incidence  by Age and 
Vaccination Status, U.S. 2001-2008
Parker Fiebelkorn et al, JID,  2010;202:1520-1528
11/24
20/58
Unvaccinated and 
traveled abroad
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Measles, United States, 2001-Present*
(Importations indicated by red bar, available since 2001)
*2014 case count preliminary as of June 20
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Measles, United States, 2001-2014*
Importations by WHO Region 
*2014 case count preliminary as of June 20
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Measles, U.S., 1997-2014*
Cumulative Number by Month of Rash Onset
* As of June 20, 2014 (data incomplete for June)
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Measles U.S. 2014*
 514 cases reported from 20 states including 16 outbreaks
 48 importations 
23 from the Philippines
43 (90%) US residents
 98% cases import-associated
 56 cases (11%) hospitalized
 Cases in US residents (N=506)
 81% unvaccinated
 12% unknown vaccination status (most are adults)
 7% vaccinated 
 Among unvaccinated
87% were personal belief exemptors
3% travelers age 6 months to 2 years 
7% were  too young to be vaccinated
3% unknown/misc
* Provisional reports to CDC through June 20, 2014 24
Measles, United States, Jan – June 20, 2014 
Source of Importations (N=48)
*Reflects travel patterns to and from the US for residents and visitors as well as measles 
activity at regional and country level
WHO Region # of cases Countries of travel
African 0
Eastern
Mediterranean
1 Pakistan
European 5 Dubai/Germany/London (1), Republic of Georgia (1), 
Netherlands (1), France/Belgium
Americas 3 Brazil (1), Canada (1), Chile (1)
South-East Asia 8 India  (6), Indonesia (1), Thailand/South Korea (1)
Western Pacific 31 China (3), Philippines (23), Singapore (1), Saipan (1), 
Vietnam (1), SE Asia/Philippines (1) , FSM (1)
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Measles Outbreaks with 20 or more Cases, 
United States, 2001-2014*
*as of June 20, 2014
Year OutbreakName State
Cases 
# Import Status Genotype Setting
1st & last 
rash onsets Duration Median Age
Age
Range
2014 Knox County OH 340*
Imported 
(Philippines)
D9 Community
3/24/2014 –
5/7/2014
12 weeks + 22 y 0 mos – 52 y
2013 Brooklyn NYC 58 Imported (UK) D8
Household/
community
3/13/2013 –
6/9/2013
13 weeks
10 y (early)
19 mos (late)
0 mos – 32 y
2005
Tippecanoe
County
IN 34
Imported 
(Romania)
D4
Church/
household
5/16/2005 -
6/24/2005
6 weeks 12 y 9 mo - 49 y
2008
DuPage/Cook
County
IL 30
Imported-
virus
D4 Homeschool
5/17/2008 -
7/3/2008
7 weeks 10 y 8 mo - 43 y
2013
Stokes/Orange
County
NC 23 Imported (India) D8 Community
4/5/2013 –
5/7/2013
5 weeks 14 y 12 mo ‐59 y
2013
Tarrant/Denton 
County
TX 21
Imported 
(Indonesia)
D9 Church
7/21/2013 –
8/21/2013
5 weeks 11 y 4 mos – 44 y
2011
Hennepin
County
MN 21
Imported
(Kenya)
B3 Shelter
2/15/2011 -
4/24/2011
10 weeks 23 m 3 mo - 51 y
2008
Brooklyn/
Kings County
NYC 21
Imported
(Israel, 
Belgium)
D4 Community
2/17/2008 -
4/25/2008
10 weeks 15 m 5 mo - 11 y
2014 Manhattan NYC 20 Imported‐virus B3 Community
2/16/2014 –
3/24/2014
5 weeks 23 y 3 mo – 36 y
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Measles outbreak response has a high 
economic burden in the U.S.
*Public health and health care costs expended to control the spread of measles
Year Location
Number of 
cases 
(outbreaks)
Estimated public health cost*
2011 US 107 (16) $2.7-5.3M
2011 Utah 13 (2) >$330,000
2008 California 12 (1) $125,000
2008 Arizona 14 (1) $800,000
(limited to cost for 2 hospitals to respond to 7 
cases in their facilities)
2005 Indiana 34 (1) $168,000
2004 Iowa 1 $142,000
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Keys to Measles Prevention
Diagnosis, & Response
 Vaccine
 Vaccine coverage to maintain high population immunity
 Measles diagnosis
 Clinical history and examination
 Specimen collection and lab testing
 Case Response
 Reporting
 Contact Investigation
 Presumptive evidence of immunity
 Isolation and Quarantine
 Post Exposure Prophylaxis
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MMR Vaccine Routine Recommendations*
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
*ACIP, AAP/COID, AAFP,  ACOG, ACP, ACNM available at  
http://www.cdc.gov/vaccines/schedules/hcp/adult.html
 Children and adolescents
 Two doses at 12-15 months and 4-6 years or at least 28 days after 
the first dose
 Catch up vaccination as needed
 Adults without evidence of measles immunity
 Two doses (healthcare personnel, post high school students, 
travelers)
 One dose (others)
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MMR Vaccine Travel Recommendations
 Persons aged ≥12 months without other evidence of 
immunity should receive 2 doses*
 Includes providing a 2nd dose to children prior to age 4-6 yrs
 Includes adults** who have only received one routine dose in the past
 Children aged 6-11 months should receive 1 dose
 If vaccinated at age 6-11 months, still need 2 subsequent doses at age 
≥12 months 
* 2nd dose of MMR vaccine should be administered at least 28 days after the 1st dose
** Born in 1957 or later
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MMR Vaccination Coverage 
National Immunization Survey, U.S., 1995-2012
NIS data available at http://www.cdc.gov/vaccines/imz-managers/coverage/imz-coverage.html
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Suspected Measles: Diagnosis and Response
 Many U.S healthcare professionals have never seen a 
case of measles
 Delay in diagnosis contributes to transmission
 Consider measles in differential diagnosis of febrile rash 
illness
 e.g. Kawasaki’s, Scarlet fever, Dengue
 Travel History or Exposure to Recent Travelers or measles in the local 
community 
 Documented Vaccine History
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
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Suspected Measles: Diagnosis and Response
 Lab testing
 Serology for IgM
 Viral specimen (nasopharyngeal, oropharyngeal, or nasal swab) for 
PCR (and genotyping)
 Acute and convalescent specimens for IgG may be useful, especially 
in vaccinated cases 
 Report immediately to local health department
 Offer vaccine or immune globulin immediately to 
household members without evidence of immunity
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
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Public Health Response
(for confirmed and suspect cases)
 Isolation of cases
 Infectious period 4 days prior through 4 days after date of rash 
onset
 Notification and Surveillance
 Immediately notifiable to CDC (within 24 hours)
 Contact CDC Quarantine Station if relevant travel
 Alert physicians statewide
 Enhanced measles surveillance
 Contact investigations and response efforts
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
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Measles Isolation Guidance
 If measles is suspected in a clinic, ER or hospital setting, 
isolate immediately
 Airborne isolation room or private room with the door 
closed, mask patient if feasible
 Ensure healthcare personnel have evidence of 
immunity
 In hospital setting, respiratory precautions including 
N95 masks or PAPR, even for those with evidence of 
immunity
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
and http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf
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Contact Investigation for Exposure to Measles
 Persons exposed during cases infectious period
 Includes exposure to area 2 hours after case left
 Establish presumptive evidence of immunity for 
contacts
 Quarantine of contacts without presumptive evidence 
of immunity (through 21 days after exposure)
 Postexposure prophylaxis (PEP)
 Vaccine or Immune globulin (IG)
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
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Presumptive Evidence of Immunity for Measles
Routine
Students at post-high 
school educational 
institutions 
Health-care personnel International travelers
(1) Documentation of
age-appropriate 
vaccination with a live 
measles virus-containing 
vaccine:
–preschool-aged 
children: 1 dose
–school-aged children 
(grades K-12): 2 doses 
–adults not at high risk: 1 
dose, or
(2) Laboratory evidence 
of immunity, or
(3) Laboratory 
confirmation of disease, 
or
(4) Born before 1957
(1) Documentation of 
vaccination with 2 doses 
of live measles virus-
containing vaccine, or
(2) Laboratory evidence 
of immunity, or 
(3) Laboratory 
confirmation of disease, 
or
(4) Born before 1957
(1) Documentation of 
vaccination with 2 doses 
of live measles virus-
containing vaccine, or
(2) Laboratory evidence 
of immunity, or 
(3) Laboratory 
confirmation of disease, 
or
(4) Born before 1957
- should consider 2 
doses
- must provide 2 doses 
during outbreak 
response unless 
serologic evidence of 
immunity 
(1) Documentation of
age-appropriate 
vaccination with a live 
measles virus-containing 
vaccine:
–infants aged 6–11 
months: 1 dose
–persons aged ≥12 
months: 2 doses, or 
(2) Laboratory evidence 
of immunity, or 
(3) Laboratory 
confirmation of disease, 
or
(4) Born before 1957
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
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Postexposure Prophylaxis (PEP)
MMR Vaccine
 Administer within 72 hours of exposure
 May return to normal activities (except health care settings)
 Still monitor for symptoms
 Can be given down to age 6 months
 Be aware of possibility of vaccine rash
2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
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Postexposure Prophylaxis (PEP)
Immune Globulin
 Administer within 6 days of exposure
 Recommended Dose
 Intramuscular (IGIM): 0.5 mL/kg (max = 15 mL)
 Intravenous (IGIV): 400 mg/kg
 Recommended for the following groups (risk of severe 
disease and complications)
Infants aged <12 months (IGIM)
Pregnant women without evidence of immunity (IGIV)
Severely immunocompromised patients (IGIV)
CDC guidance available at http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html
and 2013 ACIP Recommendations at http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
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Measles In the Postelimination Era
 Measles is due to Failure to Vaccinate
 Measles Elimination is a Global Problem
 Continued threat of importations
 Measles occurs in the U.S.
 Maintenance of Elimination is Resource Intensive
 Maintaining vaccine coverage
 Intensive case/contact investigations
 Healthcare workers diagnostic skills
 Advanced laboratory techniques
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Resources for Healthcare Professionals
http://www.cdc.gov/measles/hcp/
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 Clinical Information
 Complications 
 Transmission
 Practice Guidelines
 Diagnosis 
 Lab testing
 Isolation & Treatment
 Vaccination Recs
 Children & Adults
 International Travelers
 Measles Images
 Outbreak Statistics
Resources for Healthcare Professionals
 Webinar:  Measles 2014 Update-Clinical Presentation, Outbreaks, Vaccination 
Recommendations, & Patient Management
 http://www.vicnetwork.org/
 NetConference:  Why Measles Matters
 http://www.cdc.gov/vaccines/ed/ciinc/
 Banners and Buttons Linking to CDC Clinician Site
 http://www.cdc.gov/measles/resources/web-buttons.html
 CDC Fact Sheets and Resources
 Fact sheets on measles and vaccine safety to guide 
discussions with patients and parents
 www.cdc.gov/vaccines/hcp/patient-ed/conversations/prevent-diseases/index.html
 Put CDC’s Measles Content for Clinicians on Your Website
 Easy steps to syndicate CDC’s measles information to                                                 
your website
 https://tools.cdc.gov/syndication/pages.aspx?topicId=28032
 http://www.cdc.gov/syndication/
 Children with Measles Video
 http://www.cdc.gov/vaccines/ed/epivac/default.htm (Session 6)
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Resources for the Public
http://www.cdc.gov/measles/index.html
http://www.cdc.gov/measles/resources/index.html
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 Measles Website
 Disease Information
 Vaccination Information and Recs
 Travel Recommendations
 Outbreak Statistics
 Infographics, Videos, & Podcasts
 Measles Feature 
 http://www.cdc.gov/features/measles/
Put CDC’s Measles Content for the Public on Your Website
 https://tools.cdc.gov/syndication/pages.aspx?topicId=28032
 Resources in Spanish
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Thank You
Questions?
The findings and conclusions in this report are those of the authors 
and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
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To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click” in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter in the queue to ask a question
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Accrediting Statements
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical 
Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention 
designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit 
commensurate with the extent of their participation in the activity. 
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the 
American Nurses Credentialing Center's Commission on Accreditation.  This activity provides 1.0 contact hours.
IACET CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing 
Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to 
offer 0.1 ANSI/IACET CEU's for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education 
contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program 
is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists 
(MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing 
education contact hours available are 0. CDC provider number GA0082.
CPE:         The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy 
Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 
0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-14-129-L04-Pand enduring 0387-0000-14-129-
H04-P. This program is knowledge based.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing 
education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have 
any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
Continuing Education Credit/Contact Hours 
for COCA Calls/Webinars
Continuing Education guidelines require that the attendance of all who 
participate in COCA Conference Calls be properly documented. All 
Continuing Education credits/contact hours (CME, CNE, CEU, CECH, ACPE 
and AAVSB/RACE) for COCA Conference Calls/Webinars are issued online 
through the CDC Training & Continuing Education Online system 
http://www.cdc.gov/TCEOnline/.
Those who participate in the COCA Conference Calls and who wish to 
receive CE credit/contact hours and will complete the online evaluation by 
August 2, 2014 will use the course code WC2286(SC). Those who wish to 
receive CE credits/contact hours and will complete the online evaluation 
between August 3, 2014 and June 30, 2015 will use course code 
WD2286(SC). CE certificates can be printed immediately upon completion 
of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s 
obtained through the CDC Training & Continuing Education Online System 
will be maintained for each user. 
Centers for Disease Control and Prevention  
Atlanta, Georgia
Thank you for joining!
Please email us questions at coca@cdc.gov
http://emergency.cdc.gov/coca
Join Us on Facebook
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page today to receive COCA 
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to public health emergencies. 
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